vs
AETHLON MEDICAL INC（AEMD）与GLAUKOS Corp（GKOS）财务数据对比。点击上方公司名可切换其他公司
GLAUKOS Corp的季度营收约是AETHLON MEDICAL INC的2386.8倍（$143.1M vs $60.0K）。GLAUKOS Corp净利率更高（-93.4% vs -2926.4%，领先2833.0%）。GLAUKOS Corp自由现金流更多（$3.9M vs $-2.0M）
AETHLON MEDICAL INC是一家临床阶段医疗科技企业，专注开发针对性治疗类医疗器械，核心产品血液净化器可从血液中去除有害病毒、肿瘤外泌体及其他病原体，业务聚焦传染病和肿瘤治疗赛道，主要市场覆盖北美地区。
Glaukos Corp是一家专注于眼科领域的医疗科技企业，开发并商业化用于治疗青光眼、角膜疾病等眼部病症的微创手术器械、处方药物及消费级产品，主要市场覆盖北美、欧洲及亚太地区，为全球医院、眼科诊所及患者提供服务。
AEMD vs GKOS — 直观对比
营收规模更大
GKOS
是对方的2386.8倍
$60.0K
净利率更高
GKOS
高出2833.0%
-2926.4%
自由现金流更多
GKOS
多$5.9M
$-2.0M
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $60.0K | $143.1M |
| 净利润 | $-1.8M | $-133.7M |
| 毛利率 | — | -1.1% |
| 营业利润率 | -3026.4% | -97.7% |
| 净利率 | -2926.4% | -93.4% |
| 营收同比 | — | 35.7% |
| 净利润同比 | 49.4% | -298.0% |
| 每股收益（稀释后） | $-10.05 | $-2.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AEMDGKOS
| Q4 25 | — | $143.1M | ||
| Q3 25 | — | $133.5M | ||
| Q2 25 | — | $124.1M | ||
| Q1 25 | — | $106.7M | ||
| Q4 24 | $60.0K | $105.5M | ||
| Q3 24 | $95.1K | $96.7M | ||
| Q2 24 | — | $95.7M | ||
| Q1 24 | — | $85.6M |
净利润AEMDGKOS
| Q4 25 | — | $-133.7M | ||
| Q3 25 | — | $-16.2M | ||
| Q2 25 | — | $-19.7M | ||
| Q1 25 | — | $-18.1M | ||
| Q4 24 | $-1.8M | $-33.6M | ||
| Q3 24 | $-2.8M | $-21.4M | ||
| Q2 24 | — | $-50.5M | ||
| Q1 24 | — | $-40.8M |
毛利率AEMDGKOS
| Q4 25 | — | -1.1% | ||
| Q3 25 | — | 78.4% | ||
| Q2 25 | — | 78.3% | ||
| Q1 25 | — | 77.2% | ||
| Q4 24 | — | 72.9% | ||
| Q3 24 | — | 76.6% | ||
| Q2 24 | — | 76.4% | ||
| Q1 24 | — | 76.3% |
营业利润率AEMDGKOS
| Q4 25 | — | -97.7% | ||
| Q3 25 | — | -12.3% | ||
| Q2 25 | — | -18.3% | ||
| Q1 25 | — | -19.4% | ||
| Q4 24 | -3026.4% | -27.2% | ||
| Q3 24 | -3050.2% | -25.5% | ||
| Q2 24 | — | -31.3% | ||
| Q1 24 | — | -45.6% |
净利率AEMDGKOS
| Q4 25 | — | -93.4% | ||
| Q3 25 | — | -12.2% | ||
| Q2 25 | — | -15.8% | ||
| Q1 25 | — | -17.0% | ||
| Q4 24 | -2926.4% | -31.8% | ||
| Q3 24 | -2950.2% | -22.1% | ||
| Q2 24 | — | -52.8% | ||
| Q1 24 | — | -47.7% |
每股收益（稀释后）AEMDGKOS
| Q4 25 | — | $-2.34 | ||
| Q3 25 | — | $-0.28 | ||
| Q2 25 | — | $-0.34 | ||
| Q1 25 | — | $-0.32 | ||
| Q4 24 | $-10.05 | $-0.56 | ||
| Q3 24 | $-16.11 | $-0.39 | ||
| Q2 24 | — | $-1.00 | ||
| Q1 24 | — | $-0.82 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.8M | $90.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.3M | $656.2M |
| 总资产 | $6.5M | $893.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AEMDGKOS
| Q4 25 | — | $90.8M | ||
| Q3 25 | — | $98.2M | ||
| Q2 25 | — | $100.8M | ||
| Q1 25 | — | $114.3M | ||
| Q4 24 | $4.8M | $169.6M | ||
| Q3 24 | $6.9M | $100.1M | ||
| Q2 24 | — | $68.1M | ||
| Q1 24 | — | $42.5M |
股东权益AEMDGKOS
| Q4 25 | — | $656.2M | ||
| Q3 25 | — | $769.5M | ||
| Q2 25 | — | $765.1M | ||
| Q1 25 | — | $764.0M | ||
| Q4 24 | $4.3M | $766.9M | ||
| Q3 24 | $6.0M | $668.5M | ||
| Q2 24 | — | $665.2M | ||
| Q1 24 | — | $450.7M |
总资产AEMDGKOS
| Q4 25 | — | $893.5M | ||
| Q3 25 | — | $999.4M | ||
| Q2 25 | — | $987.0M | ||
| Q1 25 | — | $966.2M | ||
| Q4 24 | $6.5M | $974.8M | ||
| Q3 24 | $8.8M | $926.5M | ||
| Q2 24 | — | $919.7M | ||
| Q1 24 | — | $933.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.0M | $6.8M |
| 自由现金流经营现金流 - 资本支出 | $-2.0M | $3.9M |
| 自由现金流率自由现金流/营收 | -3357.0% | 2.7% |
| 资本支出强度资本支出/营收 | 3.7% | 2.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-22.5M |
8季度趋势，按日历期对齐
经营现金流AEMDGKOS
| Q4 25 | — | $6.8M | ||
| Q3 25 | — | $-10.1M | ||
| Q2 25 | — | $7.0M | ||
| Q1 25 | — | $-18.5M | ||
| Q4 24 | $-2.0M | $507.0K | ||
| Q3 24 | $-2.2M | $-9.6M | ||
| Q2 24 | — | $-18.4M | ||
| Q1 24 | — | $-33.9M |
自由现金流AEMDGKOS
| Q4 25 | — | $3.9M | ||
| Q3 25 | — | $-11.7M | ||
| Q2 25 | — | $5.8M | ||
| Q1 25 | — | $-20.5M | ||
| Q4 24 | $-2.0M | $-1.2M | ||
| Q3 24 | — | $-11.0M | ||
| Q2 24 | — | $-20.5M | ||
| Q1 24 | — | $-34.8M |
自由现金流率AEMDGKOS
| Q4 25 | — | 2.7% | ||
| Q3 25 | — | -8.8% | ||
| Q2 25 | — | 4.7% | ||
| Q1 25 | — | -19.2% | ||
| Q4 24 | -3357.0% | -1.2% | ||
| Q3 24 | — | -11.4% | ||
| Q2 24 | — | -21.4% | ||
| Q1 24 | — | -40.7% |
资本支出强度AEMDGKOS
| Q4 25 | — | 2.0% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | 3.7% | 1.6% | ||
| Q3 24 | 0.0% | 1.5% | ||
| Q2 24 | — | 2.2% | ||
| Q1 24 | — | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AEMD
暂无分部数据
GKOS
| Glaucoma | $86.4M | 60% |
| Other | $35.1M | 25% |
| Corneal Health | $21.6M | 15% |
